New treatment targets in ankylosing spondylitis and other spondyloarthritides.
作者： In-Ho Song , Denis Poddubnyy
DOI: 10.1097/BOR.0B013E328346F7FB
关键词:
摘要: … Despite overall good efficacy of currently available treatment [nonsteroidal anti-inflammatory drugs, tumor necrosis factor (TNF) α inhibitors] for ankylosing spondylitis (AS) and other …
lww.com
sci-hub.se 参考文章(70)
ME Reff, K Carner, KS Chambers, PC Chinn, JE Leonard, R Raab, RA Newman, N Hanna, DR Anderson, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood. ,vol. 83, pp. 435- 445 ,(1994) , 10.1182/BLOOD.V83.2.435.435
Aggarwal Rohit, G Rider Lisa, E Rockette Howard, W Miller Frederick, J Barohn Richard, M Feldman Brian, V Oddis Chester, P Ascherman Dana, M Reed Ann, リツキシマブ治療を行った難治性成人および若年性皮膚筋炎(DM)と成人多発性筋炎(PM)における臨床的反応の予測因子-RIM試験 Arthritis & Rheumatism. ,vol. 62, pp. 3840- ,(2010)
Christi Parham, Madaline Chirica, Jacqueline Timans, Elena Vaisberg, Marilyn Travis, Jeanne Cheung, Stefan Pflanz, Rebecca Zhang, Komal P. Singh, Felix Vega, Wayne To, Janet Wagner, Anne-Marie O’Farrell, Terrill McClanahan, Sandra Zurawski, Charles Hannum, Daniel Gorman, Donna M. Rennick, Robert A. Kastelein, Rene de Waal Malefyt, Kevin W. Moore, A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R Journal of Immunology. ,vol. 168, pp. 5699- 5708 ,(2002) , 10.4049/JIMMUNOL.168.11.5699
Philip Seo, Ulrich Specks, Karina A Keogh, None, Efficacy of Rituximab in Limited Wegener's Granulomatosis with Refractory Granulomatous Manifestations The Journal of Rheumatology. ,vol. 35, pp. 2017- 2023 ,(2008)
Maria Bokarewa, Catharina Lindholm, Andrej Tarkowski, Katharina Börjesson-Asp, Anna-Carin Sundqvist, Kiandokht Zendjanchi, Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. The Journal of Rheumatology. ,vol. 35, pp. 826- 833 ,(2008)
A. Falkenbach, M. Herold, In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatology International. ,vol. 18, pp. 103- 106 ,(1998) , 10.1007/S002960050066
Sjef Van Der Linden, Hans A. Valkenburg, Arnold Cats, Evaluation of Diagnostic Criteria for Ankylosing Spondylitis Arthritis & Rheumatism. ,vol. 27, pp. 361- 368 ,(1984) , 10.1002/ART.1780270401
J Zou, Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Annals of the Rheumatic Diseases. ,vol. 64, pp. 722- 729 ,(2005) , 10.1136/ARD.2004.024455
John C. Davis, D�sir�e Van Der Heijde, Jurgen Braun, Maxime Dougados, John Cush, Daniel O. Clegg, Alan Kivitz, Roy Fleischmann, Robert Inman, Wayne Tsuji, , Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis & Rheumatism. ,vol. 48, pp. 3230- 3236 ,(2003) , 10.1002/ART.11325
Hui Shen, Jane C. Goodall, J. S. Hill Gaston, Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis & Rheumatism. ,vol. 60, pp. 1647- 1656 ,(2009) , 10.1002/ART.24568